Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer (ZIDON)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2014 by National Cancer Institute, Naples
Information provided by (Responsible Party):
National Cancer Institute, Naples Identifier:
First received: September 30, 2009
Last updated: December 29, 2014
Last verified: December 2014

Neuropathic pain is difficult to control because it is only partially sensitive to opioid analgesics, and requires the addition of other therapies such as antidepressants and epileptics. Ziconotide is a drug that is used to treat neuropathic pain in patients who have had inadequate pain control with prior combination of medicines.

Condition Intervention Phase
Neuropathic Pain
Intractable Pain
Drug: ziconotide
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Intrathecal Ziconotide for the Treatment of Neuropathic Pain in Patients With Cancer

Resource links provided by NLM:

Further study details as provided by National Cancer Institute, Naples:

Primary Outcome Measures:
  • Response rate (> 30% reduction in VASPI) [ Time Frame: 48 hours after completion of titration phase ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • toxicity [ Time Frame: daily during drug titration, weekly thereafter ] [ Designated as safety issue: Yes ]
  • duration of analgesic response [ Time Frame: weekly ] [ Designated as safety issue: No ]

Estimated Enrollment: 16
Study Start Date: September 2009
Estimated Study Completion Date: September 2015
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: ziconotide
intrathecal ziconotide starting at 2.4 micrograms/day, with titration daily to achieve adequate pain control up to maximum dose of 21.6 micrograms/day

Detailed Description:

The purpose of this study is to evaluate the effects and the tolerability of intrathecal ziconotide in cancer patients suffering from severe neuropathic pain not controlled by previous therapies.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of neoplasm
  • Neuropathic pain level VASPI > or = 6 (0-10 scale)
  • Inadequate pain relief with opioid analgesics and adjuvants
  • Age > or = 18 years
  • Performance status ECOG 0-2
  • Life expectancy at least one month
  • Adequate contraception in women of child-bearing potential
  • Signed Informed Consent

Exclusion Criteria:

  • Use of experimental drugs within previous 30 days
  • Pregnancy or lactation
  • Contraindication to the use of intrathecal analgesics, including active infection or conditions that could alter the circulation of cerebrospinal fluid
  • Presence of cerebral metastasis
  • INR > 2
  • Contraindication to the use of ziconotide
  • Unable or unwilling to provide informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00996983

Contact: Francesco Perrone, M.D., Ph.D. +390815903571
Contact: Massimo Di Maio, M.D. +390815903631 massimo.dimaio@usc-intnapoli.lnet

Istituto Nazionale dei Tumori , Unita Terapia Antalgica Recruiting
Napoli, Italy
Sponsors and Collaborators
National Cancer Institute, Naples
Principal Investigator: Arturo Cuomo, M.D. NCI Naples, Division of Pain Therapy
Principal Investigator: Gennaro Russo, M.D. NCI Naples, Division of Pain Therapy
Principal Investigator: Alessandro Morabito, M.D. NCI Naples, Clinical Trials Unit
  More Information

No publications provided

Responsible Party: National Cancer Institute, Naples Identifier: NCT00996983     History of Changes
Other Study ID Numbers: ZIDON, EudraCT number: 2008-005307-26
Study First Received: September 30, 2009
Last Updated: December 29, 2014
Health Authority: Italy: Ethics Committee

Additional relevant MeSH terms:
Nervous System Diseases
Neurologic Manifestations
Neuromuscular Diseases
Peripheral Nervous System Diseases
Signs and Symptoms
Analgesics, Non-Narcotic
Calcium Channel Blockers
Cardiovascular Agents
Central Nervous System Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neuroprotective Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Sensory System Agents
Therapeutic Uses processed this record on March 30, 2015